---
title: "United Therapeutics Corporation (UTHR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/UTHR.US.md"
symbol: "UTHR.US"
name: "United Therapeutics Corporation"
industry: "Biotechnology"
datetime: "2026-04-16T21:26:21.822Z"
locales:
  - [en](https://longbridge.com/en/quote/UTHR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/UTHR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/UTHR.US.md)
---

# United Therapeutics Corporation (UTHR.US)

## Company Overview

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.unither.com](https://www.unither.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: B (0.29)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 10 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 10.61% |  |
| Net Profit YoY | 11.68% |  |
| P/B Ratio | 3.57 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25313994879.88 |  |
| Revenue | 3182700000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 19.71% | A |
| Profit Margin | 41.94% | A |
| Gross Margin | 87.92% | A |
| Revenue YoY | 10.61% | B |
| Net Profit YoY | 11.68% | C |
| Total Assets YoY | 7.01% | B |
| Net Assets YoY | 10.12% | B |
| Cash Flow Margin | 116.97% | B |
| OCF YoY | 10.61% | B |
| Turnover | 0.42 | C |
| Gearing Ratio | 9.95% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - United Therapeutics Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "10.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "11.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.57",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "25313994879.88",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3182700000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "19.71%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "41.94%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "87.92%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "10.61%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.68%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.01%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.12%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "116.97%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "10.61%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "9.95%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 18.97 | 39/393 | 16.54 | 15.63 | 11.11 |
| PB | 3.57 | 261/393 | 3.18 | 2.76 | 1.97 |
| PS (TTM) | 7.95 | 146/393 | 6.73 | 6.35 | 4.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-10T04:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 60% |
| Overweight | 2 | 13% |
| Hold | 4 | 27% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 580.51 |
| Highest Target | 733.00 |
| Lowest Target | 471.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/UTHR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/UTHR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/UTHR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/UTHR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**